市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Replimune Group, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
-0.4
| 分析师共识 | NA |
| 内部交易活动 | -3.0 |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | -0.38 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 4.51% |
| 机构持股比例 | 107.50% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Ridgeback Capital Investments L.P. | 30 Jun 2026 | 7,310,656 |
| Boxer Capital Management, Llc | 30 Jun 2026 | 3,983,000 |
| Fcpm Iii Services B.V. | 30 Jun 2026 | 2,808,368 |
| Erste Asset Management Gmbh | 30 Jun 2026 | 2,120,000 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| HILL EMILY LUISA | - | 13.67 | -11,448 | -156,494 |
| PATEL SUSHIL | - | 13.67 | -39,341 | -537,791 |
| SCHWENDENMAN ANDREW | - | 13.67 | -7,632 | -104,329 |
| XYNOS KONSTANTINOS | - | 13.67 | -11,447 | -156,480 |
| 累积净数量 | -69,868 | |||
| 累积净值 ($) | -955,096 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 13.67 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| SCHWENDENMAN ANDREW | 职员 | 10 Aug 2026 | 卖 (-) | 7,632 | 13.67 | 104,329 |
| XYNOS KONSTANTINOS | 职员 | 10 Aug 2026 | 卖 (-) | 11,447 | 13.67 | 156,480 |
| HILL EMILY LUISA | 职员 | 10 Aug 2026 | 卖 (-) | 11,448 | 13.67 | 156,494 |
| PATEL SUSHIL | 职员 | 10 Aug 2026 | 卖 (-) | 39,341 | 13.67 | 537,791 |
| 日期 | 类型 | 细节 |
|---|---|---|
| 17 Jun 2026 | CNBC | UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency |
| 29 May 2026 | CNBC | Replimune to resubmit twice-rejected drug for approval after FDA shakeup |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合